Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 25, 2009

iThemba Pharmaceuticals and Pyxis Discovery to Commingle Service Offerings

  • iThemba Pharmaceuticals' service division and Pyxis Discovery signed a collaborative agreement to jointly market each other’s services. Pyxis' computational chemistry and lead discovery expertise will be coupled with iThemba's service division to provide medicinal and synthetic chemistry support to projects identified through Pyxis' international client network.

    iThemba Pharmaceuticals and Pyxis Discovery also inked a co-marketing agreement to offer virtual libraries that will be exclusively synthesized for clients.

    iThemba Pharmaceuticals, which is based in South Africa, was founded to discover and develop new and affordable medicines for the diseases of poverty in Africa. The company is funded by the Biotechnology Regional Innovation Centers, LIFElab, and BioPAD of the Department of Science and Technology, Government of South Africa.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »